Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Industry Gets Breathing Space For Post-Brexit Regulation In Northern Ireland

One-Year Phase-In Period Addresses Pharma’s ‘Cliff Edge’ Concerns

Executive Summary

The pharmaceutical industry has welcomed a decision to allow more time to bring in new medicines regulations in Northern Ireland, but continues to insist that a mutual recognition agreement between the UK and the EU on drug manufacturing is the best way forward.

You may also be interested in...



Brexit: Companies Must ‘Act Now’ To Avoid Drug Supply Disruptions In 2021

In its latest letter to medicines and medical product companies, the UK's Department of Health and Social Care says the biggest potential cause of disruption to supplies could be failure to prepare for border controls implemented by the EU member states after the end of the Brexit transition period.

Brexit: New Rules Will Hit Parallel Trade From UK to EU

From next year, owners of trademarks and other rights in the European Economic Area will be able to prevent the parallel export of medicines from the UK to the EEA. But those owning similar rights in the UK will not be able to stop parallel imports from EEA countries. 

Stepping Back From The Cliff Edge: UK Industry Welcomes Northern Ireland Brexit Extension

Companies supplying into Northern Ireland now have more time to prepare for post-Brexit regulatory changes in areas like batch testing, imports and Falsified Medicines Directive requirements. UK industry association, PAGB, in a joint statement with five other pharmaceutical industry associations, including AESGP, describes it as a step in the right direction, but also warns that there is still much work to do.

Related Content

Topics

UsernamePublicRestriction

Register

LL1134531

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel